NovaBay Pharmaceuticals, Inc.
NBY
$0.60
$0.000.00%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -4.62% | |||
| Total Other Revenue | -- | -117.65% | |||
| Total Revenue | -- | -5.41% | |||
| Cost of Revenue | -- | -4.83% | |||
| Gross Profit | -- | -5.71% | |||
| SG&A Expenses | -2.88% | 4.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.93% | 2.74% | |||
| Operating Income | -109.54% | -21.49% | |||
| Income Before Tax | -151.70% | -9.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -151.70% | -9.16% | |||
| Earnings from Discontinued Operations | 9,809.91% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 732.84% | 0.00% | |||
| EBIT | -109.54% | -21.49% | |||
| EBITDA | -110.69% | -21.77% | |||
| EPS Basic | 1,053.17% | 74.63% | |||
| Normalized Basic EPS | -212.09% | 48.81% | |||
| EPS Diluted | 1,053.17% | 74.63% | |||
| Normalized Diluted EPS | -206.00% | 48.81% | |||
| Average Basic Shares Outstanding | -33.61% | 115.50% | |||
| Average Diluted Shares Outstanding | -32.27% | 115.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||